Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
23andMe, the maker of genetic testing kits for consumers, is partnering with pharmaceutical giant GlaxoSmithKline to develop new drugs. The companies will share both the costs and revenues of the new venture, and GSK also announced a $300 million investment in 23andMe at the same time.
How it works: The idea behind this partnership is to leverage the vast amounts of clinical information 23andMe collects, to help develop products that are highly tailored to specific groups of patients.
23andMe already was selling its data to outside pharma companies, and a spokesperson tells Axios that such agreements will not be affected by the GSK partnership.
More from the 23andMe spox:
"During the four-year agreement with GSK, 23andMe will not engage in new target drug discovery collaborations, but it will continue to work with third parties on other meaningful collaborations. This includes helping with clinical trials and working with researchers on specific communities based on phenotypic data collection to understand patient symptoms, preferences, market research, etc."